Literature DB >> 32956720

RANKL as a key figure in bridging between the bone and immune system: Its physiological functions and potential as a pharmacological target.

Masashi Honma1, Yuki Ikebuchi1, Hiroshi Suzuki2.   

Abstract

RANKL is a key molecule that bridges the bone and immune systems. RANKL stimulation activates a signaling pathway downstream of RANK, thereby determining the extent of bone resorption by inducing osteoclast maturation. The signaling pathway also regulates the development of different lymphoid organs, including the thymus, lymph nodes, and Peyer's patches, and plays an essential role in the establishment of immune tolerance. Such characteristics have continued to attract the attention of many researchers, even though it is now more than 20 years since RANKL was identified as a novel member of the TNF superfamily. Recently, we found that RANKL can function not only as a signal input molecule but also as a signal receptor to activate the RANKL reverse signaling pathway, which mediates the coupling between bone resorption and formation. This new finding may provide an important basis for elucidating the complex physiological roles played by RANKL.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bone; Immune system; Osteoimmunology; RANKL

Mesh:

Substances:

Year:  2020        PMID: 32956720     DOI: 10.1016/j.pharmthera.2020.107682

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  5 in total

1.  Dual effect of IL-7/IL-7R signalling on the osteoimmunological system: a potential therapeutic target for rheumatoid arthritis.

Authors:  Haiyan Xu; Li Cai; Zijian Li; Lili Zhang; Guojue Wang; Rongli Xie; Yongshuai Jiang; Yuanyang Yuan; Hong Nie
Journal:  Immunology       Date:  2021-06-02       Impact factor: 7.215

Review 2.  Lipid metabolism within the bone micro-environment is closely associated with bone metabolism in physiological and pathophysiological stages.

Authors:  Bo Wang; Heng Wang; Yuancheng Li; Lei Song
Journal:  Lipids Health Dis       Date:  2022-01-07       Impact factor: 3.876

3.  Azilsartan Suppresses Osteoclastogenesis and Ameliorates Ovariectomy-Induced Osteoporosis by Inhibiting Reactive Oxygen Species Production and Activating Nrf2 Signaling.

Authors:  Bin Pan; Lin Zheng; Jiawei Fang; Ye Lin; Hehuan Lai; Jiawei Gao; Wenzheng Pan; Yejin Zhang; Kainan Ni; Chao Lou; Dengwei He
Journal:  Front Pharmacol       Date:  2021-11-26       Impact factor: 5.810

4.  α-Mangostin inhibits LPS-induced bone resorption by restricting osteoclastogenesis via NF-κB and MAPK signaling.

Authors:  Wenkan Zhang; Guangyao Jiang; Xiaozhong Zhou; Leyi Huang; Jiahong Meng; Bin He; Yiying Qi
Journal:  Chin Med       Date:  2022-03-05       Impact factor: 5.455

Review 5.  Biosimilar monoclonal antibodies in China: A patent review.

Authors:  Jia-Wei Liu; Yu-Huan Yang; Nan Wu; Ji-Fu Wei
Journal:  Bioengineered       Date:  2022-06       Impact factor: 6.832

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.